Astroglial and oligodendroglial markers in the cuprizone animal model for de- and remyelination.
Astrocytes
Cuprizone
Demyelination
Multiple sclerosis
Journal
Histochemistry and cell biology
ISSN: 1432-119X
Titre abrégé: Histochem Cell Biol
Pays: Germany
ID NLM: 9506663
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
accepted:
26
02
2022
pubmed:
6
4
2022
medline:
6
7
2022
entrez:
5
4
2022
Statut:
ppublish
Résumé
Myelin loss with consecutive axon degeneration and impaired remyelination are the underlying causes of progressive disease in patients with multiple sclerosis. Astrocytes are suggested to play a major role in these processes. The unmasking of distinct astrocyte identities in health and disease would help to understand the pathophysiological mechanisms in which astrocytes are involved. However, the number of specific astrocyte markers is limited. Therefore, we performed immunohistochemical studies and analyzed various markers including GFAP, vimentin, S100B, ALDH1L1, and LCN2 during de- and remyelination using the toxic murine cuprizone animal model. Applying this animal model, we were able to confirm overlapping expression of vimentin and GFAP and highlighted the potential of ALDH1L1 as a pan-astrocytic marker, in agreement with previous data. Only a small population of GFAP-positive astrocytes in the corpus callosum highly up-regulated LCN2 at the peak of demyelination and S100B expression was found in a subset of oligodendroglia as well, thus S100B turned out to have a limited use as a particular astroglial marker. Additionally, numerous GFAP-positive astrocytes in the lateral corpus callosum did not express S100B, further strengthening findings of heterogeneity in the astrocytic population. In conclusion, our results acknowledged that GFAP, vimentin, LCN2, and ALDH1L1 serve as reliable marker to identify activated astrocytes during cuprizone-induced de- and remyelination. Moreover, there were clear regional and temporal differences in protein and mRNA expression levels and patterns of the studied markers, generally between gray and white matter structures.
Identifiants
pubmed: 35380252
doi: 10.1007/s00418-022-02096-y
pii: 10.1007/s00418-022-02096-y
pmc: PMC9246805
doi:
Substances chimiques
Biomarkers
0
Vimentin
0
Cuprizone
5N16U7E0AO
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15-38Informations de copyright
© 2022. The Author(s).
Références
Histol Histopathol. 2011 Dec;26(12):1585-97
pubmed: 21972097
ASN Neuro. 2012 Oct 30;4(6):393-408
pubmed: 23025787
J Biol Chem. 2014 Jun 13;289(24):16773-89
pubmed: 24808182
Front Cell Neurosci. 2014 Mar 13;8:73
pubmed: 24659953
PLoS One. 2011;6(7):e22623
pubmed: 21818353
Neurotox Res. 2017 May;31(4):570-577
pubmed: 28124768
Acta Neuropathol. 2010 Jan;119(1):7-35
pubmed: 20012068
Prog Neurobiol. 2011 Mar;93(3):421-43
pubmed: 21219963
Front Neuroanat. 2018 Oct 30;12:90
pubmed: 30425626
J Biol Chem. 2011 Dec 23;286(51):43855-43870
pubmed: 22030398
J Neurosci Res. 2008 Dec;86(16):3494-502
pubmed: 18816798
Biochim Biophys Acta. 2012 Aug;1826(1):129-69
pubmed: 22513004
Mol Cell Neurosci. 2004 Dec;27(4):453-65
pubmed: 15555923
Nat Neurosci. 2015 Jul;18(7):942-52
pubmed: 26108722
Physiol Rev. 2018 Jan 1;98(1):239-389
pubmed: 29351512
Invest Ophthalmol Vis Sci. 2015 Jun;56(6):3691-8
pubmed: 26047170
Nat Rev Neurol. 2012 Nov 5;8(11):647-56
pubmed: 23007702
Front Neurol. 2015 Aug 18;6:180
pubmed: 26347709
Mol Cells. 2009 Apr 30;27(4):397-401
pubmed: 19390819
Front Immunol. 2017 Sep 20;8:1171
pubmed: 28979267
Mol Brain. 2021 Oct 6;14(1):154
pubmed: 34615523
J Neuroinflammation. 2011 Sep 26;8:124
pubmed: 21943033
Biochim Biophys Acta. 2004 Dec 6;1742(1-3):169-77
pubmed: 15590067
Curr Mol Med. 2013 Jan;13(1):24-57
pubmed: 22834835
Glia. 2007 Oct;55(13):1300-12
pubmed: 17626262
J Mol Neurosci. 2013 Jan;49(1):80-8
pubmed: 23054589
J Immunol. 2020 Feb 1;204(3):586-595
pubmed: 31889023
Sci Rep. 2016 Feb 25;6:21950
pubmed: 26911537
Neurosci Biobehav Rev. 2015 Feb;49:135-56
pubmed: 25511817
FASEB J. 2013 Mar;27(3):1176-90
pubmed: 23207546
Brain. 2006 Dec;129(Pt 12):3165-72
pubmed: 16921173
Brain Pathol. 2001 Jan;11(1):107-16
pubmed: 11145196
J Mol Neurosci. 2015 Oct;57(2):166-75
pubmed: 26067430
Microsc Res Tech. 2003 Apr 15;60(6):614-32
pubmed: 12645009
Front Immunol. 2018 Feb 19;9:217
pubmed: 29515568
Neuroscience. 1993 May;54(1):15-36
pubmed: 8515840
Acta Neuropathol. 2012 May;123(5):627-38
pubmed: 22327362
PLoS One. 2016 Apr 07;11(4):e0152480
pubmed: 27054832
J Neurochem. 2016 Oct;139(2):181-186
pubmed: 27454326
J Cereb Blood Flow Metab. 2008 Mar;28(3):450-5
pubmed: 17895910
Neurology. 2014 Jul 15;83(3):278-86
pubmed: 24871874
Cell. 2001 Aug 24;106(4):489-98
pubmed: 11525734
J Neurosci. 2008 Jan 2;28(1):264-78
pubmed: 18171944
J Neurosci Res. 2011 Jan;89(1):13-21
pubmed: 20857501
Biochem J. 1996 Aug 15;318 ( Pt 1):1-14
pubmed: 8761444
Glia. 2013 Sep;61(9):1533-41
pubmed: 23836537
F1000Res. 2016 Dec 30;5:2934
pubmed: 28149504
Physiol Rev. 2014 Oct;94(4):1077-98
pubmed: 25287860
PLoS One. 2014 Jul 10;9(7):e101881
pubmed: 25010215
J Neurosci. 2009 Jan 7;29(1):234-49
pubmed: 19129400
Prog Brain Res. 2001;132:23-30
pubmed: 11544992
J Neurosci. 2011 Sep 21;31(38):13412-9
pubmed: 21940434
BMC Neurosci. 2007 Jan 02;8:2
pubmed: 17199889
J Neurosci. 2017 Sep 6;37(36):8706-8717
pubmed: 28821665
Glia. 2005 Aug 1;51(2):81-97
pubmed: 15782413
J Neurochem. 2019 Jan;148(2):168-187
pubmed: 30144068
J Neurosci. 2013 Feb 13;33(7):3113-30
pubmed: 23407966
Cell Mol Life Sci. 2008 Sep;65(17):2702-20
pubmed: 18516496
J Cereb Blood Flow Metab. 2012 Mar;32(3):413-24
pubmed: 22214904
Genomics. 1997 Oct 1;45(1):17-23
pubmed: 9339356
Ann Neurol. 2000 Jun;47(6):707-17
pubmed: 10852536
Glia. 2011 Feb;59(2):200-7
pubmed: 21046559
Nat Commun. 2018 Aug 3;9(1):3066
pubmed: 30076300
Stroke. 2014 Jul;45(7):2085-92
pubmed: 24916903
Brain. 2013 Jan;136(Pt 1):147-67
pubmed: 23266461
Methods Mol Biol. 2012;814:23-45
pubmed: 22144298
Neuroscientist. 2010 Feb;16(1):79-106
pubmed: 20236950
Neurol Neuroimmunol Neuroinflamm. 2016 Jan 07;3(1):e191
pubmed: 26770997
Neuroscience. 1998 Apr;83(3):857-66
pubmed: 9483569
Brain Pathol. 2003 Jul;13(3):329-39
pubmed: 12946022
Prog Neurobiol. 2015 Aug;131:120-36
pubmed: 26159707
Neurosci Lett. 1995 Feb 15;186(1):13-6
pubmed: 7783941
J Mol Neurosci. 2021 Nov;71(11):2237-2248
pubmed: 33346907
Nat Commun. 2019 Aug 29;10(1):3887
pubmed: 31467299
J Immunol. 2013 Nov 15;191(10):5204-19
pubmed: 24089194
J Immunol. 1993 Aug 1;151(3):1535-47
pubmed: 8335946
Nature. 2016 Apr 14;532(7598):195-200
pubmed: 27027288
Neurosci Res. 2012 Jan;72(1):32-42
pubmed: 22015947
Glia. 2012 Jul;60(7):1145-59
pubmed: 22499213
Brain Pathol. 2007 Apr;17(2):210-8
pubmed: 17388952
Neurochem Res. 2010 Jan;35(1):114-21
pubmed: 19655246
Glia. 2019 Jan;67(1):171-181
pubmed: 30430665
J Biol Chem. 1999 Aug 20;274(34):23996-4006
pubmed: 10446168
Lab Anim. 2002 Jan;36(1):20-42
pubmed: 11831737
Nature. 2004 Dec 16;432(7019):917-21
pubmed: 15531878
Nat Rev Neurosci. 2002 Sep;3(9):705-14
pubmed: 12209119
Brain Res. 2009 Aug 4;1283:127-38
pubmed: 19524552
Glia. 2014 Dec;62(12):2022-33
pubmed: 25043249
Histol Histopathol. 2015 Dec;30(12):1455-64
pubmed: 26110560
Cells. 2020 Apr 11;9(4):
pubmed: 32290524
Chem Biol Interact. 2009 Mar 16;178(1-3):84-93
pubmed: 18848533
Front Cell Neurosci. 2012 Aug 09;6:33
pubmed: 22907989
Glia. 1996 Jun;17(2):169-74
pubmed: 8776583
Glia. 2007 Jan 15;55(2):165-77
pubmed: 17078026
J Biol Chem. 1993 May 15;268(14):10425-32
pubmed: 7683678
Acta Neuropathol. 2001 Jul;102(1):1-10
pubmed: 11547943
Brain Pathol. 1994 Jul;4(3):229-37
pubmed: 7952264
Mol Neurobiol. 2016 Aug;53(6):3976-3991
pubmed: 26184632
J Cell Biol. 1981 Aug;90(2):435-47
pubmed: 7026573
J Neuroimmunol. 1998 Dec 1;92(1-2):38-49
pubmed: 9916878
Neuroscience. 1999;91(2):661-72
pubmed: 10366023
J Neurol Sci. 1973 Sep;20(1):73-83
pubmed: 4744512
Glia. 2014 Oct;62(10):1659-70
pubmed: 24909143
J Immunol. 2007 Sep 1;179(5):3231-41
pubmed: 17709539
Exp Neurol. 2016 Sep;283(Pt B):541-9
pubmed: 26988764